Label: OFLOXACIN solution/ drops

  • NDC Code(s): 50383-024-05, 50383-024-10
  • Packager: Hi-Tech Pharmacal Co., Inc.
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated October 5, 2020

If you are a consumer or patient please visit this version.


    Ofloxacin ophthalmic solution 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use.

    Chemical Name:

    (±)-9-Fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid

    Ofloxacin Structural Formula


    Active: ofloxacin 0.3% (3 mg/mL).

    Preservative: benzalkonium chloride (0.005%).

    Inactives: sodium chloride and purified water. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH.

    Ofloxacin ophthalmic solution is unbuffered and formulated with a pH of 6.4 (range - 6.0 to 6.8). It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4-quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure.



    Serum, urine and tear concentrations of ofloxacin were measured in 30 healthy women at various time points during a ten-day course of treatment with ofloxacin ophthalmic solution. The mean serum ofloxacin concentration ranged from 0.4 ng/mL to 1.9 ng/mL. Maximum ofloxacin concentration increased from 1.1 ng/mL on day one to 1.9 ng/mL on day 11 after QID dosing for 10 1/2 days. Maximum serum ofloxacin concentrations after ten days of topical ophthalmic dosing were more than 1000 times lower than those reported after standard oral doses of ofloxacin.

    Tear ofloxacin concentrations ranged from 5.7 to 31 µg/g during the 40 minute period following the last dose on day 11. Mean tear concentration measured four hours after topical ophthalmic dosing was 9.2 µg/g.

    Corneal tissue concentrations of 4.4 µg/mL were observed four hours after beginning topical ocular application of two drops of ofloxacin ophthalmic solution every 30 minutes. Ofloxacin was excreted in the urine primarily unmodified.


    Ofloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. Ofloxacin is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Ofloxacin is thought to exert a bactericidal effect on susceptible bacterial cells by inhibiting DNA gyrase, an essential bacterial enzyme which is a critical catalyst in the duplication, transcription, and repair of bacterial DNA.

    Cross-resistance has been observed between ofloxacin and other fluoroquinolones. There is generally no cross-resistance between ofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides.

    Ofloxacin has been shown to be active against most strains of the following organisms both in vitro and clinically, in conjunctival and/or corneal ulcer infections as described in the INDICATIONS AND USAGE section.



    Staphylococcus aureus

    Enterobacter cloacae

    Staphylococcus epidermidis

    Haemophilus influenzae

    Streptococcus pneumoniae

    Proteus mirabilis


    Pseudomonas aeruginosa

    Propionibacterium acnes

    Serratia marcescens*

    *Efficacy for this organism was studied in fewer than 10 infections

    The safety and effectiveness of ofloxacin ophthalmic solution in treating ophthalmologic infections due to the following organisms have not been established in adequate and well-controlled clinical trials. Ofloxacin ophthalmic solution has been shown to be active in vitro against most strains of these organisms but the clinical significance in ophthalmologic infections is unknown.


    Enterococcus faecalis

    Staphylococcus hominus

    Listeria monocytogenes

    Staphylococcus simulans

    Staphylococcus capitis

    Streptococcus pyogenes


    Acinetobacter calcoaceticus var. anitratus

    Klebsiella pneumoniae

    Acinetobacter calcoaceticus var. Iwoffii

    Moraxella (Branhamella) catarrhalis

    Citrobacter diversus

    Moraxella lacunata

    Citrobacter freundii

    Morganella morganii

    Enterobacter aerogenes

    Neisseria gonorrhoeae

    Enterobacter agglomerans

    Pseudomonas acidovorans

    Escherichia coli

    Pseudomonas fluorescens

    Haemophilus parainfluenzae

    Shigella sonnei

    Klebsiella oxytoca


    Chlamydia trachomatis

    Clinical Studies:


    In a randomized, double-masked, multicenter clinical trial, ofloxacin ophthalmic solution was superior to its vehicle after 2 days of treatment in patients with conjunctivitis and positive conjunctival cultures. Clinical outcomes for the trial demonstrated a clinical improvement rate of 86% (54/63) for the ofloxacin treated group versus 72% (48/67) for the placebo treated group after 2 days of therapy. Microbiological outcomes for the same clinical trial demonstrated an eradication rate for causative pathogens of 65% (41/63) for the ofloxacin treated group versus 25% (17/67) for the vehicle treated group after 2 days of therapy. Please note that microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.

    Corneal Ulcers:

    In a randomized, double-masked, multi-center clinical trial of 140 subjects with positive cultures, ofloxacin ophthalmic solution treated subjects had an overall clinical success rate (complete re-epithelialization and no progression of the infiltrate for two consecutive visits) of 82% (61/74) compared to 80% (53/66) for the fortified antibiotic group, consisting of 1.5% tobramycin and 10% cefazolin solutions. The median time to clinical success was 11 days for the ofloxacin treated group and 10 days for the fortified treatment group.


    Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:


    Gram-positive bacteria:

    Gram-negative bacteria:

    Staphylococcus aureus

    Staphylococcus epidermidis

    Streptococcus pneumoniae

    Enterobacter cloacae

    Haemophilus influenzae

    Proteus mirabilis

    Pseudomonas aeruginosa


    Gram-positive bacteria:

    Gram-negative bacteria:

    Staphylococcus aureus

    Staphylococcus epidermidis

    Streptococcus pneumoniae

    Pseudomonas aeruginosa

    Serratia marcescens*

    Anaerobic species:

    Propionibacterium acnes

    *Efficacy for this organism was studied in fewer than 10 infections


    Ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.



    Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.

    Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin. If an allergic reaction to ofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management, including intubation should be administered as clinically indicated.



    As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. Ofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction.

    The systemic administration of quinolones, including ofloxacin, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species. Ofloxacin, administered systemically at 10 mg/kg/day in young dogs (equivalent to 110 times the maximum recommended daily adult ophthalmic dose) has been associated with these types of effects.

    Information for patients

    Avoid contaminating the applicator tip with material from the eye, fingers or other source.

    Systemic quinolones, including ofloxacin, have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction.

    Drug interactions

    Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

    Carcinogenesis, mutagenesis, impairment of fertility

    Long term studies to determine the carcinogenic potential of ofloxacin have not been conducted.

    Ofloxacin was not mutagenic in the Ames test, in vitro and in vivo cytogenic assay, sister chromatid exchange assay (Chinese hamster and human cell lines), unscheduled DNA synthesis (UDS) assay using human fibroblasts, the dominant lethal assay, or mouse micronucleus assay. Ofloxacin was positive in the UDS test using rat hepatocyte, and in the mouse lymphoma assay.

    In fertility studies in rats, ofloxacin did not affect male or female fertility or morphological or reproductive performance at oral dosing up to 360 mg/kg/day (equivalent to 4000 times the maximum recommended daily ophthalmic dose).


    Teratogenic effects

    Pregnancy Category C: Ofloxacin has been shown to have an embryocidal effect in rats and in rabbits when given in doses of 810 mg/kg/day (equivalent to 9000 times the maximum recommended daily ophthalmic dose) and 160 mg/kg/day (equivalent to 1800 times the maximum recommended daily ophthalmic dose). These dosages resulted in decreased fetal body weight and increased fetal mortality in rats and rabbits, respectively. Minor fetal skeletal variations were reported in rats receiving doses of 810 mg/kg/day. Ofloxacin has not been shown to be teratogenic at doses as high as 810 mg/kg/day and 160 mg/kg/day when administered to pregnant rats and rabbits, respectively.

    Nonteratogenic effects

    Additional studies in rats with doses up to 360 mg/kg/day during late gestation showed no adverse effect on late fetal development, labor, delivery, lactation, neonatal viability, or growth of the newborn.

    There are, however, no adequate and well-controlled studies in pregnant women. Ofloxacin ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Nursing mothers

    In nursing women a single 200 mg oral dose resulted in concentrations of ofloxacin in milk which were similar to those found in plasma. It is not known whether ofloxacin is excreted in human milk following topical ophthalmic administration. Because of the potential for serious adverse reactions from ofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    Pediatric use

    Safety and effectiveness in infants below the age of one year have not been established.

    Quinolones, including ofloxacin, have been shown to cause arthropathy in immature animals after oral administration; however, topical ocular administration of ofloxacin to immature animals has not shown any arthropathy. There is no evidence that the ophthalmic dosage form of ofloxacin has any effect on weight bearing joints.

    Geriatric use

    No overall differences in safety or effectiveness have been observed between elderly and younger patients.


    To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or

    Ophthalmic Use:

    The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness and nausea have been received.


    The recommended dosage regimen for the treatment of bacterial conjunctivitis is:

    Days 1 and 2

    Instill one to two drops every two to four hours in the affected eye(s).

    Days 3 through 7

    Instill one to two drops four times daily.

    The recommended dosage regimen for the treatment of bacterial corneal ulcer is:

    Days 1 and 2

    Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops.

    Days 3 through 7 to 9

    Instill one to two drops hourly, while awake.

    Days 7 to 9 through treatment completion

    Instill one to two drops, four times daily.


    Ofloxacin ophthalmic solution 0.3% is supplied sterile in opaque white LDPE plastic bottles and white dropper tips with beige high impact polystyrene (HIPS) caps as follows:

    5 mL - NDC 50383-024-05

    10 mL - NDC 50383-024-10

    Note: Store at 20-25°C (68 - 77°F) [see USP Controlled Room Temperature].

    Manufactured by:

    Hi-Tech Pharmacal Co., Inc.

    Amityville, NY 11701

    Rev. 12/08 MG #24681


    Image of Carton - 10 mL

    NDC 50383-024-10

    Ofloxacin Ophthalmic Solution 0.3%


    10 mL

    Rx only

    ofloxacin solution/ drops
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:50383-024
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:50383-024-101 in 1 CARTON05/14/2004
    110 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    2NDC:50383-024-051 in 1 CARTON05/14/2004
    25 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - Hi-Tech Pharmacal Co., Inc. (117696873)
    Registrant - Akorn Operating Company LLC (117693100)
    NameAddressID/FEIBusiness Operations
    Hi-Tech Pharmacal Co., Inc.117696873MANUFACTURE(50383-024) , PACK(50383-024) , ANALYSIS(50383-024)